title: In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance.
abstract: Selenium nanoparticles (Se NPs) were prepared based on the reduction of selenious acid (H(2)SeO(3)), by employing sodium alginate (SA) as a template. The real-time monitoring of the drug-inducing apoptosis process of human hepatic cancer cells Bel7402 was performed with the quartz crystal microbalance (QCM) measurement. The anti-tumor effect of adriamycin (ADM) used in combination with Se NPs was investigated. It is found that both drugs were able to inhibit cell proliferation in a dose-dependent way and the combined treatment with ADM and Se NPs was more effective in inhibiting cell growth than each of the two drugs alone. The cytotoxic effects of drug combination were evaluated with the modified Bürgi formula (Jin equation) based the Deltaf(0) responses. The grades gradually changed from apparent synergism to simple addition with the drug-treatment time increasing but the drug combination with lower concentrations still exhibited synergism after 24h, suggesting a potential application in cancer therapy.
authors.affiliation: State Key Laboratory of Chemo/Biological Sensing and Chemometrics, Hunan University, Changsha 410082, PR China.
authors.forename: Liang
authors.initials: L
authors.lastname: Tan
authors.forename: Xue'en
authors.initials: X
authors.lastname: Jia
authors.forename: Xiangfu
authors.initials: X
authors.lastname: Jiang
authors.forename: Youyu
authors.initials: Y
authors.lastname: Zhang
authors.forename: Hao
authors.initials: H
authors.lastname: Tang
authors.forename: Shouzhuo
authors.initials: S
authors.lastname: Yao
authors.forename: Qingji
authors.initials: Q
authors.lastname: Xie
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage*; D004357:Drug Synergism; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology*; D055617:Micro-Electrical-Mechanical Systems / Q000295:instrumentation*; D053758:Nanoparticles / Q000627:therapeutic use; D012643:Selenium / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D012643:Selenium